People · Operator
Named in public records as an officer, director or promoter · active 2013–2013 · Biotechnology
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Boston Therapeutics, Inc. | — | Biotechnology | Series A | $12.5M | $189.9M | 2013 |
David Platt, Ph. D. at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside David Platt, Ph. D. on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| David Platt | 1 | 4 |
| Dale H. Conaway | 1 | 3 |
| David Ludvigson | 1 | 2 |
| Henry H. Esber | 1 | 1 |
| Kenneth Tassey, Jr. | 1 | 1 |
| Colin W. Neill | 1 | 1 |
| Henry W. Esber | 1 | 1 |
| Carl W. Rausch | 1 | 1 |
| Dale W. Conway | 1 | 1 |
| Rom W. Eliaz | 1 | 1 |
| Conroy Chi-Heng Cheng | 1 | 1 |
| Alan W. Hoberman | 1 | 1 |
| Kenneth A. Tassey, Jr. | 1 | 1 |
| Carl H. Lueders | 1 | 1 |
| Rom H. Eliaz | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.